Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase
Authors:
- Christopher M. ReillyCRChristopher M. Reilly
- Libby W. FarrellyLFLibby W. Farrelly
- Dana VitiDVDana Viti
- Shakisha T. RedmondSRShakisha T. Redmond
- Florence HutchisonFHFlorence Hutchison
- Phil RuizPRPhil Ruiz
- Pam ManningPMPam Manning
- Jane ConnorJCJane Connor
- Gary S. GilkesonGGGary S. Gilkeson
- 1 March 2002
- journal article
- research article
- Published by Elsevier in Kidney International
- Vol. 61 (3) , 839-846
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- The Genetics of Systemic Lupus ErythematosusScandinavian Journal of Immunology, 1999
- A Large Blood Pressure–Raising Effect of Nitric Oxide Synthase Inhibition in HumansHypertension, 1999
- Adoptively Transferred EAE in Mice Bearing thelprMutationClinical Immunology and Immunopathology, 1997
- Molecular mechanisms of experimental glomerulonephritis: an overviewNephrology, 1997
- NITRIC OXIDE AND MACROPHAGE FUNCTIONAnnual Review of Immunology, 1997
- Regulation of nitric oxide synthase gene expressionby cytokinesJournal of Cardiac Failure, 1996
- The nitric oxide pathway in glomerulonephritisCurrent Opinion in Nephrology and Hypertension, 1995
- Structure and function of nitric of oxide synthasesInternational Journal of Cardiology, 1994
- Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions.Hypertension, 1994
- Arginase is a major pathway of L-arginine metabolism in nephritic glomeruliKidney International, 1992